by Defence Therapeutics | Sep 29, 2026 | News Release
Montreal, QC, Canada, September 29, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®... 
by Defence Therapeutics | Sep 28, 2026 | News Release
Montreal, QC, Canada, September 28, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”) (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®... 
by Defence Therapeutics | Sep 8, 2026 | News Release
Montreal, QC, Canada, September 8, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®... by Defence Therapeutics | Sep 4, 2026 | News Release
Montreal, QC, Canada, September 4, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to provide an update on its sharing...
Recent Comments